Toll-like receptor signaling mechanisms involved in dendritic cell activation: Potential therapeutic control of T cell polarization

Current Pharmaceutical Design

Volumn 12, Issue 32, 2006, Pages 4247-4254

  Amati, Luigi ^a   Pepe, Maria ^b   Passeri, Maria Elena ^a   Mastronardi, Maria Letizia ^b   Jirillo, Emilio ^a,b   Covelli, Vito ^c  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c POLICLINICO   (Italy)

Author keywords

Cytokines; DC homing; Inflammatory bowel disease (IBD); Mannose receptor (MR); TIR domaincontaining adaptor protein (TIRAP)

Indexed keywords

ADAPTOR PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; BETA GLUCAN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; DECTIN 1; DOCOSAHEXAENOIC ACID; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 10; LAURIC ACID; MAJOR HISTOCOMPATIBILITY ANTIGEN; MANNOSE RECEPTOR; OUTER MEMBRANE PROTEIN; POLYNUCLEOTIDE; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; CELL SURFACE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG MECHANISM; HUMAN; ILEITIS; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SCIENTIFIC LITERATURE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

DENDRITIC CELLS; HUMANS; SIGNAL TRANSDUCTION; TH1 CELLS; TH2 CELLS; TOLL-LIKE RECEPTORS;

EID: 33750562781     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778743583     Document Type: Review

References (104)

1. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106: 255-8.
2. Tan JKH, O'Neil H C. Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity. J Leukoc Biol 2005; 78: 319-24.
3. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 2002; 111: 927-30.
4. Mazzoni A, Segal DM. Controlling the Toll road to dendritic cell polarization. J Leukoc, Biol 2004; 75: 721-30.
5. Lembo A, Kalis C, Kirschning CJ, Mitolo V, Jirillo E, Wagner H, et al. Differential contribution of Toll-like receptors 4 and 2 to the cytokine response to Salmonella enterica, Serovar typhimurium and Staphylococcus aureus in mice. Infect Immun 2003; 71: 6058-62.
6. Bell JK, Mullen GED, Leifer CA, Mazzoni A, Davies DR, Segal DM. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 2003; 24: 528-33.
7. Poltorak A, He X, Smimova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 1998; 282: 2085-8.
8. Pulendran B. Variegation of the immune response with dendritic cells and pathogen recognition receptors. J Immunol 2005; 174: 2457-65.
9. Uehori J, Fukase K, Akazawa T, Vematsu S, Akira S, Funami K, et al. Dendritic cell maturation induced by muramyl dipeptide (MDP) derivative: monoacylated MDP confers TLR2/TLR4 activation. J Immunol; 2005; 174: 7096-103.
10. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511
11. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60.
12. Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 2001; 13: 291-8.
13. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999; 20: 561-7.
14. Murphy KK Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2: 933-44.
15. Smits HH, de Jong EC, Wierenga EA, Kapsenberg ML. Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol 2005; 26: 123-9.
16. Haeryfar SM. The importance of being a pDC in antiviral immunity: the IFN mission versus Ag presentation? Trends Immunol 2005; 26: 311-7.
17. Ardavin C. Origin, precursors and differentiation of mouse dendritic cells. Nat Rev Immunol 2003; 3: 582-90.
18. Edwards AD, Diebold SS, Slack EM, Tomizawa H, Hemmi H, Kaisho T, et al. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 2003; 33: 827-33.
19. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183-6.
20. Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza vinis and CD40L drive a potent TH1 polarization. Nat Immunol 2000; 1: 305-10.
21. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31: 3026-37.
22. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195: 1507-12.
23. Huang Q, Liu D, Majewski P, Schulte LC, Kom JM, Young RA, et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001; 294: 870-5.
24. Pulendran B, Kumar P, Cutler CW, Mohamadzadeh M, Van Dyke T, Banchereau J. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol 2001; 167: 5067-76.
25. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 2001; 276: 37692-9.
26. Artis D, Kane MC, Fiore J, Zaph C, Shapira S, Joyle K, et al. Dendritic cell-intrinsic expression of NF-kappa B1 is required to promote optimal Th2 cell differentiation. J Immunol 2005; 174: 7154-9.
27. Flynn S, Toellner KM, Raykundalia C, Goodall M, Lane P. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med 1998; 188: 297-304.
28. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg W, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000; 164: 4507-12.
29. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 2003; 171: 2366-73.
30. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
31. Kalinski P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001; 97: 3466-9.
32. Kamath AT, Sheasby CE, Tough DF. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J Immunol 2005; 174: 767-76.
33. Bennouna S, Bliss SK, Curiel TJ, Denkers EY. Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J Immunol 2003; 171: 6052-8.
34. Caron G, Delneste Y, Roelandts E, Duez C, Bonnefoy JY, Pestel J, et al. Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells. J Immunol 2001; 167: 3682-6.
35. Faveeuw C, Gosset P, Bureau F, Angeli V, Hirai H, Maruyama T, et al. Prostaglandin D2 inhibits the production of interleukin-12 in murine dendritic cells through multiple signaling pathways. Eur J Immunol 2003; 33: 889-98.
36. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human epithelial cells trigger dendritic cell- mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3: 673-80.
37. Janssens S, Beyaert R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci 2002; 27: 474-82.
38. Medvedev AE, Lentschat A, Kuhns DB, Blanco JC, Salkowski C, Zhang S, et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 2003; 198: 521-31.
39. Li S, Strelow A, Fontana EJ, Wesche H. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA 2002; 99: 5567-72.
40. Kobayashi T, Walsh PT, Walsh MC, Speirs KM, Chiffoleau E, King CG, et al. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 2003; 19: 353-63.
41. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2001; 2: 835-41.
42. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301: 640-3.
43. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003; 424: 743-8.
44. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003; 4: 1144-50.
45. Dillon S, Agrawal A, Van Dyke T, Landreth G, McCauley L, Koh A, et al. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol 2004; 172: 4733-43.
46. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T, et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003; 171: 4984-9.
47. Lugo-Villarino G, Maldonado-Lopez R, Possemato R, Penaranda C, Glimcher LH. T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci USA 2003; 100: 7749-54.
48. Laderach D, Compagno D, Danos O, Vainchenker W, Galy A. RNA interference shows critical requirement for NF-kappa B p50 in the production of IL-12 by human dendritic cells. J Immunol 2003; 171: 1750-7.
49. Mason N, Aliberti J, Caamano JC, Liou HC, Hunter CA. Cutting edge: identification of c-Rel-dependent and -independent pathways of IL-12 production during infectious and inflammatory stimuli. J Immunol 2002; 168: 2590-4.
50. Cao S, Liu J, Chesi M, Bergsagel PL, Ho IC, Donnelly RP, et al. Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. J Immunol 2002; 169: 5715-25.
51. Appelmelk BJ, van Die I, van Vliet SJ, Vandenbroucke-Grauls CM, Geijtenbeek TB, van Kooyk Y. Cutting edge: carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-grabbing nonintegrin on dendritic cells. J Immunol 2003; 170: 1635-9.
52. Giordano D, Maialetti DM, Clark EA, Beavo JA. Cyclic nucleotides promote monocyte differentiation toward a DC-SIGN+ (CD209) intermediate cell and impair differentiation into dendritic cells. J Immunol 2003; 171: 6421-30.
53. Harshyne LA, Zimmer MI, Watkins SC, Barratt-Boyes SM. A role for class A scavenger receptor in dendritic cell nibbling from live cells. J Immunol 2003; 170: 2302-9.
54. East L, Isacke CM. The mannose receptor family. Biochim Biophys Acta 2002; 1572: 364-86.
55. Le Cabec V, Emorine LJ, Toesca I, Cougoule C, Maridonneau-Parini I. The human macrophage mannose receptor is not a professional phagocytic receptor. J Leukoc Biol 2005; 77: 934-43.
56. Chiappa M, Bianchi G, Doni A, Del Prete A, Sironi M, Laskarin G, et al. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immmunosuppressive program. J Immunol 2003; 171: 4552-60.
57. Amati L, Leogrande D, Passeri ME, Mastronardi ML, Passantino L, Venezia P, et al. β-Glucans: old molecules with newly discovered immunologocal activities. Drug Design Rev Online 2005; 2: 251-58.
58. Herre J, Gordon S, Brown GD. Dectin-1 and its role in the recognition of beta-glucans by macrophages. Mol Immunol 2004; 40: 869-76.
59. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 2003; 197: 1107-17.
60. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004; 5: 800-8.
61. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
62. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
63. Amati L, Caradonna L, Jirillo E, Caccavo D. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications. Ital J Gastroenterol Hepatol 1999; 31: 313-25.
64. Caradonna L, Amati L, Magrone T, Pellegrino NM, Jirillo E, Caccavo D. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res 2000; 6: 205-14.
65. Amati L, Passeri ME, Mastronardi ML, Jirillo E. Anti tumor necrosis factor- alfa (Infliximab) therapy in patients with inflammatory bowel disease (IBD): application and side effects. Drug Des Rev Online 2004; 1: 111-17.
66. Amati L, Caradonna L, Magrone T, Manghisi C, Leandro G, Caccavo D, et al. In vitro effects of naloxone on T-lymphocyte-dependent antibacterial activity in hepatitis C virus (HCV) infected patients and in inflammatory bowel disease (IBD) patients. Immunopharmacol Immunotoxicol 2001; 23: 1-11.
67. Caradonna L, Amati L, Lella P, Jirillo E, Caccavo D. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease. Am J Gastroenterol 2000; 95: 1495-502.
68. Amati L, Caradonna L, Leandro G, Magrone T, Minenna M, Faleo G, et al. Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: attempts at neutralizing endotoxin-mediated effects. Curr Pharm Des 2003; 9: 1937-45.
69. Beutler B. Autoimmunity and apoptosis: the Crohn's connection. Immunity 2001; 15: 5-14.
70. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, Viala J, et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003; 300: 1584-7.
71. Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003; 4: 702-7.
72. Takada H, Uehara A. Enhancement of TLR-Mediated Innate Immune Responses by Peptidoglycans through NOD signaling. Curr Pharm Design 2006; 12: 000-000.
73. Williamson E, Westrich GM, Viney JL. Modulating dendritic cells to optimize mucosal immunization protocols. J Immunol 1999; 163: 3668-75.
74. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14: 461-70.
75. Boyaka PN, Tafaro A, Fischer R, Fujihashi K, Jirillo E, McGhee JR. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity. Curr Pharm Des 2003; 9: 1965-72.
76. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 2002; 99: 1676-82.
77. Colino J, Snapper CM. Dendritic cells, new tools for vaccination. Microbes Infect 2003; 5: 311-9.
78. Demangel C, Britton WJ. Interaction of dendritic cells with mycobacteria: where the action starts. Immunol Cell Biol 2000; 78: 318-24.
79. Mbow ML, Zeidner N, Panella N, Titus RG, Piesman J. Borrelia burgdorferi-pulsed dendritic cells induce a protective immune response against tick-transmitted spirochetes. Infect Immun 1997; 65: 3386-90.
80. Shaw J, Grund V, Durling L, Crane D, Caldwell HD. Dendritic cells pulsed with a recombinant chlamydial major outer membrane protein antigen elicit a CD4(+) type 2 rather than type 1 immune response that is not protective. Infect Immun 2002; 70: 1097-105.
81. Bacci A, Montagnoli C, Perruccio K, Bozza S, Gaziano R, Pitzurra L, et al. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J Immunol 2002; 168: 2904-13.
82. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59: 3340-5.
83. Famularo G, Mosca L , Minisola G, Trinchieri V, De Simone C. Probiotic lactobacilli: a new perspective for the treatment of inflammatory bowel disease. Curr Pharm Des 2003; 9: 1973-80.
84. Drakes M, Blanchard T, Czinn S. Bacterial probiotic modulation of dendritic cells. Infect Immun 2004, 72: 3299-309.
85. Simpson SJ, Shah S, Comiskey M, de Jong YP, Wang B, Mizoguchi E, et al. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells. J Exp Med 1998; 187: 1225-34.
86. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190: 995-1004.
87. Ulisse S, Gionchetti P, D'Alo S, Russo FP, Pesce I, Ricci G, et al. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001; 96: 2691-9.
88. Weatherill AR, Lee JY, Zhao L, Lemay DG, Youn HS, Hwang DH. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J Immunol 2005; 174: 5390-7.
89. Michelsen KS, Doherty TM, Shah PK, Arditi M. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 2004; 173: 5901-7.
90. Ishida BY, Blanche PJ, Nichols AV, Yashar M, Paigen B. Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J Lipid Res 1991; 32: 559-68.
91. O'Neill HC, Wilson H. Limitations with in vitro production of dendritic cells using cytokines. J Leukoc Biol 2004; 75: 600-603.
92. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005; 26: 447-54.
93. Milling SWF, Cousins L, MacPherson GG. How do DCs interact with intestinal antigens? Trends Immunol 2005; 26: 349-52.
94. Kaiserlian D, Cerf-Bensussan N, Hosmalin A. The mucosal immune system: from control of inflammation to protection against infections. J Leukoc Biol 2005; 78: 311-8.
95. Flano E, Kayhan B, Woodland D L, Blackman M A. Infection of dendritic cells by a γ2-herpesvirus induces functional modulation. J Immunol 2005; 175: 3325-34.
96. Ikeda Y, Adachi Y, Ishibashi K-I, Miura N, Ohno N. Activation of toll-like receptor-mediated NF-kappa beta by zymosan-derived water-soluble fraction: possible contribution of endotoxin-like substances. Immunopharmacol Immunotoxicol 2005; 27: 285-98.
97. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 102: 2992-7.
98. Constans A. The immune immunity adaptor list grows. The Scimtist 2005; 19: 18-9.
99. Scumpia O P, Mc Auliffe P F, O'Malley K A, Ungano R, Uccida T, Matsumoto T, et al. CD11c+ dendritic cells are required for survival in murine polymicrobial sepsis. J Immunol 2005; 175: 3282-6.
100. Iwamoto S, Ispida M, Takahashi K, Takeda K, Miyazaki A. Lipopolysaccharide stimulation converts vigorously washed dendritic cells (DCs) to nonexhausted DCs expressing CD70 and evoking long-casting type 1 T cell responses. J Leukoc Biol 2005; 78: 383-92.
101. Paterson AM, Yates SF, Nolan KF, Waldmann H. The new immunosuppression: intervention at the dendritic cell-T-cell interface. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 397-411.
102. Frantz S, Bauersachs J, Kelly RA. Innate immunity and the heart. Curr Pharm Des 2005; 11(10): 1279-90.
103. Furnkranz A, Leitinger N. Regulation of inflammatory responses by oxidized phospholipids: structure-function relationships. Curr Pharm Des 2004; 10(8): 915-21.
104. Schlichting CL, Schareck WD, Weis M. Dendritic cell endothelium interaction in autoimmunity. Curr Pharm Des 2004; 10(2): 171-81.